NCT03590652: An ongoing trial by University of California, San Diego
This trial is ongoing. It must report results 11 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT03590652 |
|---|---|
| Title | Phase II Study of the Combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma A University of California Hematologic Malignancies Consortium Protocol (UCHMC1809) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Oct. 17, 2018 |
| Completion date | March 1, 2025 |
| Required reporting date | March 1, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | March 28, 2025 |
| Days late | None |